dc.contributor | Universitat Ramon Llull. Facultat de Ciències de la Salut Blanquerna | |
dc.contributor.author | Carralero-Martínez, Andrea | |
dc.contributor.author | Muñoz Pérez, Miguel Ángel | |
dc.contributor.author | Kauffmann, Stéphanie | |
dc.contributor.author | Blanco Ratto, Laia | |
dc.contributor.author | Ramírez García, Inés | |
dc.date.accessioned | 2024-01-22T21:30:02Z | |
dc.date.available | 2024-01-22T21:30:02Z | |
dc.date.created | 2022-02 | |
dc.date.issued | 2022-04 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14342/3762 | |
dc.description.abstract | Aim
To evaluate the efficacy of adjuvant, capacitive resistive monopolar radiofrequency (CRMRF, INDIBA) treatment at 448 kHz together with physiotherapeutic techniques compared to a sham treatment with the same techniques, for pain reduction and quality of life (QoL) improvements in patients with chronic pelvic pain syndrome (CPPS).
Methods
A triple-blind, randomized controlled trial (RCT) including patients with CPPS randomly allocated (1:1) to a CRMRF-activated group (intervention) or a CRMRF-deactivated one (control). Both groups received physiotherapeutic techniques and pain education weekly for 10 consecutive weeks. Data from a visual analogical scale and the SF-12 questionnaire were collected at trial commencement and repeated at the 5th and 10th sessions. Pain intensity was considered the main outcome. For the comparisons between variables, the χ2 and Student's t test were used. Superiority was analyzed by estimating the mean change (95% confidence interval). Analysis was performed for the per-protocol and the intention-to-treat populations. The statistical significance level was set at p < 0.05.
Results
Eighty-one patients were included (67.9% women) with a mean age of 43.6 years (SD 12.9). CRMRF lessened pain scores by more than 2 points and improved QoL by 5 points. There were no relevant side effects and overall adherence to the treatment was 86.4%.
Conclusions
This is the first RCT that evaluates the efficacy of CRMRF (INDIBA) compared to a sham treatment, and demonstrates its superiority in decreasing pain and improving QoL. Such results may lead to greater prescribing of CRMRF when treating CPPS patients. | ca |
dc.format.extent | 11 p. | ca |
dc.language.iso | eng | ca |
dc.publisher | Wiley Online Library | ca |
dc.relation.ispartof | Neurourology and urodynamics, 2022, 41:962‐972 | ca |
dc.rights | © L'autor/a | ca |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.other | Bufeta -- Dolor | ca |
dc.subject.other | Aparell genital -- Dolor | ca |
dc.subject.other | Dolor pelvià | ca |
dc.subject.other | Radiofreqüència | ca |
dc.subject.other | INDIBA | ca |
dc.subject.other | Fisioteràpia | ca |
dc.subject.other | Qualitat de vida | ca |
dc.subject.other | Assaigs clínics | ca |
dc.title | Efficacy of capacitive resistive monopolar radiofrequency in the physiotherapeutic treatment of chronic pelvic pain syndrome: a randomized controlled trial | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
dc.embargo.terms | cap | ca |
dc.subject.udc | 615 | ca |
dc.subject.udc | 616.7 | ca |
dc.identifier.doi | https://doi.org/10.1002/nau.24903 | ca |
dc.description.version | info:eu-repo/semantics/publishedVersion | ca |